Table 1 Demographics and baseline characteristics of patients with baseline UPCR ≥ 1
Demographics (n = 180) | |
|---|---|
Sex: female | 156 (86.7%) |
Age, mean (SD) | 35.2 (11.4) |
Ethnicity: Hispanic | 59 (32.7%) |
Race | |
Asian | 29 (16.1%) |
Black | 76 (42.2%) |
White | 53 (29.4%) |
Other/unknown | 22 (12.2%) |
First biopsy | 62 (34.0%) |
UPCR, mean [IQR] | 3.5 [1.60–4.38] |
Nephrotic proteinuria | 82 (45.6%) |
Serum creatinine mg/dL, mean [range] (n = 179) | 1.25 [0.4–7.4] |
High serum creatinine (n = 179)a | 46 (25.7%) |
Low C3 (n = 178)a | 116 (65.2%) |
Low C4 (n = 178)a | 102 (57.3%) |
Serum albumin g/dL, mean [range] (N = 171) | 3.1 [1.0–4.7] |
Positive anti-dsDNA (n = 176) | 124 (70.5%) |
Biopsy class | |
[III] | 30 (16.7%) |
[IV] | 35 (19.4%) |
[V] | 51 (28.3%) |
[III][IV] | 3 (1.7%) |
[III][V] | 36 (20.0%) |
[IV][V] | 25 (13.9%) |
Activity Index, mean [range] (n = 143) | 5.4 [0–18] |
Chronicity Index, mean [range] (n = 143) | 3.3 [0–10] |
Extra renal activity on hybrid SELENA-SLEDAIb | 87 (48.3%) |
Medicationsc | |
Hydroxychloroquine Daily average dose [range] | 137 (76.1%) 356.1 mg [85.7–800] |
Prednisone/methylprednisolone Daily average dose [range] Pulse steroids | 135 (75.0%) 24.4 mg [2.5–120] 21 (11.7%) |
Mycophenolate mofetil Daily average dose [range] Mycophenolic acid Daily average dose [range] | 116 (6.44%) 2435.3 mg [500–3000] 8 (4.4%) 1215 mg [360–2880] |
Cyclophosphamide | 24 (13.3%) |
Azathioprine | 6 (3.3%) |
Tacrolimus | 19 (10.6%) |
Belimumab | 4 (2.2%) |
Leflunomide | 1 (0.6%) |